NCT05474963

Brief Summary

This study is to build a cohort of sudden sensorineural hearing loss (SSNHL) patients. When the patient visited the Department of otolaryngology clinic for hearing loss, we can diagnose the SSNHL following the result of pure tone audiometry and the history of the patient. The cohort is a system that tracks the hearing recovery status, timing, and degree of recovery of patients who received cocktail therapy with or without high-dose steroids, vasodilators, antiviral agents, and intratympanic steroid injections, satellite ganglion block, and hyperbaric oxygen therapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
117mo left

Started Jul 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress33%
Jul 2021Dec 2035

Study Start

First participant enrolled

July 14, 2021

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

June 6, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 26, 2022

Completed
9.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2031

Expected
4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2035

Last Updated

March 26, 2025

Status Verified

March 1, 2025

Enrollment Period

10.5 years

First QC Date

June 6, 2022

Last Update Submit

March 23, 2025

Conditions

Keywords

Hearing LossHearing Loss, suddenSSNHLSudden sensorineural hearing losssudden sensory neural hearing loss

Outcome Measures

Primary Outcomes (5)

  • Hearing outcome 1 week - PTA

    Hearing change status near 1 weak after treatment start measured by pure tone audiometry1

    1 week PTA

  • Hearing outcome 3 weeks - PTA

    Hearing change status near 3 weaks after treatment start measured by pure tone audiometry

    3 weeks PTA

  • Hearing outcome 2 months - PTA

    Hearing change status near 3 weaks after treatment start measured by pure tone audiometry

    2 month PTA

  • Hearing outcome 3 months - PTA

    Hearing change status near 3 months after treatment start measured by pure tone audiometry

    3 month PTA

  • Hearing outcome 6 months - PTA

    Hearing change status near 6 months after treatment start measured by pure tone audiometry, which is final.

    6 months PTA

Secondary Outcomes (1)

  • Electrolytes and chemistries after high dose steroid therapy

    5 days electrolytes and chemistries

Other Outcomes (1)

  • Internal Acoustic canal MRI

    MRI

Study Arms (1)

SSNHL treated with WSCH protocol

SSNHL treated with WSCH protocol

Eligibility Criteria

Age20 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Among the adults over 20yrs of age, diagnosed sudden sensorineural hearing loss at Wonju Severance Christian Hospital, Department of otolaryngology.

You may qualify if:

  • Adult patients over 20 years of age
  • A patient who visited Wonju Severance Christian Hospital, Department of Otolaryngology and was diagnosed with sudden hearing loss as it was confirmed that hearing loss of 30dBHL or more occurred within 3 days at three consecutive frequencies in a pure tone audiometry test.
  • Those who have fully explained the purpose and content of the study and voluntarily agreed to the written consent

You may not qualify if:

  • If the patients do not want to or do not fill out the consent form
  • If treatment is started for sudden hearing loss, but the possibility of other inner ear diseases including Meniere's disease is suspected due to repeated hearing loss, repeated recovery, dizziness, tinnitus, etc.
  • Other cases where it is judged difficult to carry out the clinical trial due to the judgment of the person in charge of the above clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yonsei University Wonju Severance Christian Hospital

Wŏnju, Gangwon-do, 26426, South Korea

RECRUITING

Related Publications (5)

  • Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, Hollingsworth DB, Kelley DM, Kmucha ST, Moonis G, Poling GL, Roberts JK, Stachler RJ, Zeitler DM, Corrigan MD, Nnacheta LC, Satterfield L. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45. doi: 10.1177/0194599819859885.

    PMID: 31369359BACKGROUND
  • Moon IS, Kim J, Lee SY, Choi HS, Lee WS. How long should the sudden hearing loss patients be followed after early steroid combination therapy? Eur Arch Otorhinolaryngol. 2009 Sep;266(9):1391-5. doi: 10.1007/s00405-009-0932-9. Epub 2009 Mar 13.

    PMID: 19283405BACKGROUND
  • Moon IS, Lee JD, Kim J, Hong SJ, Lee WS. Intratympanic dexamethasone is an effective method as a salvage treatment in refractory sudden hearing loss. Otol Neurotol. 2011 Dec;32(9):1432-6. doi: 10.1097/MAO.0b013e318238fc43.

    PMID: 22089956BACKGROUND
  • Rhee TM, Hwang D, Lee JS, Park J, Lee JM. Addition of Hyperbaric Oxygen Therapy vs Medical Therapy Alone for Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018 Dec 1;144(12):1153-1161. doi: 10.1001/jamaoto.2018.2133.

    PMID: 30267033BACKGROUND
  • Park SM, Han C, Lee JW, Kong TH, Seo YJ. Does Herpes Virus Reactivation Affect Prognosis in Idiopathic Sudden Sensorineural Hearing Loss? Clin Exp Otorhinolaryngol. 2017 Mar;10(1):66-70. doi: 10.21053/ceo.2016.00360. Epub 2016 Jul 27.

    PMID: 27459199BACKGROUND

MeSH Terms

Conditions

Hearing Loss, SuddenHearing Loss

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Tae Hoon Kong, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 6, 2022

First Posted

July 26, 2022

Study Start

July 14, 2021

Primary Completion (Estimated)

December 31, 2031

Study Completion (Estimated)

December 31, 2035

Last Updated

March 26, 2025

Record last verified: 2025-03

Locations